Navigation Links
Co-Inventor of Amgen's Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals' First-in-Class Oxygen Enhancing Therapeutics
Date:12/21/2007

CHARLOTTESVILLE, Va., Dec. 21 /PRNewswire/ -- Diffusion Pharmaceuticals LLC, a clinical stage drug-development company commercializing first-in-class drugs utilizing a novel mechanism of action that enhances oxygen diffusion, today announced that one of its key advisors, Mr. Thomas Byrne, was recently recognized as a co-inventor of the underlying technology of Amgen's blockbuster drug Aranesp(R) (darbepoietin alpha), a erythropoiesis stimulating agent (US Patent No. 7,217,689).

Mr. Byrne, who is an Officer of Diffusion Pharmaceuticals and a member of its Board of Directors, has directed the worldwide intellectual property strategy of the Company since its inception in February 2001. His experience includes in-house counsel positions within both Genentech and Amgen.

"We are exceptionally fortunate to have such an experienced pharmaceutical development executive with scientific acumen and expertise in related intellectual property law leading our worldwide patent strategy and helping to guide the company," says David G. Kalergis, Diffusion Pharmaceuticals' Chief Executive Officer.

About Diffusion Pharmaceuticals LLC

Diffusion Pharmaceuticals LLC is a clinical-stage drug-development company commercializing a family of first-in-class drug candidates to treat serious or life-threatening medical conditions. These proprietary small molecules use a novel method of action to enhance oxygen diffusion to oxygen deprived (hypoxic) tissue. Potential clinical applications include critical care uses such as trauma, hemorrhage, stroke and heart attack, and cancer as well as chronic conditions such as cardiovascular disease, respiratory disorders, anemia and peripheral vascular disease. Enhanced diffusion of oxygen into hypoxic tissue has an important application in oncology by improving the efficacy of radiation therapy in cancerous tumors. The Company's first Phase I clinical trial for its lead molecule, trans sodium crocetinate (TSC), shows the
'/>"/>

SOURCE Diffusion Pharmaceuticals LLC
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. Novel Technology Breaks Through Cancer Pain
3. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
4. Advanced Cell Technology Announces Proposed Financing
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
10. China Technology Announces New Chief Financial Officer
11. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...,, CALGARYandBLENHEIM,Ontario,Nov.24/PRNewsw...yitisacquiringtheassetsofHylandSeeds,adivisionofTh...ndSeedswillfurtherexpandDowAgroSciences,currentsee... SmartStax(TM) in 2010 andDowAgroSciencesHerbici...onalcloseisexpectedinthenearfuture. ,, "Thisacq...
(Date:11/24/2009)...,, REYKJAVIK,Iceland,November24/PRNewswire-F...yannouncedtheapprovalofallofits,"firstday"motionsb...he"BankruptcyCourt").deCODElastweekfiledavoluntary...ankruptcyCodewiththe,BankruptcyCourt. , Theor...tinue,tooperateitsbusinessduringtheChapter11procee...
(Date:11/24/2009)...,, SEATTLE,Nov.24/PRNewswire/--BlueMarbleEne...blicDevelopmentAuthority(OPDA)wererecentlyawarded$...lizationBoard(CERB)inaprivate/publicpartnershiptoc...neryinLincolnCounty,WA. ,, "Thisinvestmentwills...bringover70greenjobstoLincolnCounty,"saidBlueMarbl...
(Date:11/24/2009)...,, DUBLIN,November24/PRNewswire-FirstCall/--...tybiopharmaceuticalcompany,today,announcedthatitha...glucerasealfa,thecompany,senzymereplacementtherapy....Thisisthethirdmarketing,applicationforvelaglucera...sintheUnitedStatesandCanada. , Basedonaglobal...
Breaking Biology Technology:Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3
...ril 15 /PRNewswire-FirstCall/ - Angiotech Pharmace...specialty pharmaceutical and,medical device compan...,position as a non-executive director of the Compa...n his numerous business pursuits and additional,bo...,s Board of Directors,since 2005. This position wi...
...udy shows naturally occurring antibodies contained...prit for Alzheimer,s disease, CHICAGO, April 15 ...and Baxter International Inc. (NYSE: BAX ) today,...ng natural antibodies,contained in GAMMAGARD LIQUI...keted as KIOVIG in the European Union, a plasma-de...
...la., and CEDARHURST, N.Y., April 15 ,BioHorizons, ...n of its,purchase of Implant Logic Systems, Ltd. (...nt Logic Systems will operate as a subsidiary of,B...ented, "We are excited,to expand our product offer...ing software and CAD/CAM surgical guides. This acq...
Other Biology Technology:Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 2Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 3Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 4Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 5BioHorizons Announces the Purchase of Implant Logic Systems 2
(Date:11/24/2009)... Stents that keep weakened and flabby arteries fr...r six months, those stents are no longer needed --...nnecessary. Previously, doctors had no choice but ... of Tel Aviv University,s Department of Biomedical...ber platform that carries drugs where they,re need...
(Date:11/24/2009)..., BATON ROUGE Antarctica has long held secrets ...nd until recently, there has been very little info...beneath miles of ice for millions of years. Now, a...ding LSU have been funded to the tune of $10 mill... NSF, to get to the bottom of things literally. T...
(Date:11/23/2009)... CINCINNATINew research presents strong evidence ...re to both outdoor traffic-related pollution and i...gs than one or the other exposure alone. , Env...Cincinnati (UC) College of Medicine have shown tha...related particles and indoor endotoxin during earl...
Breaking Biology News(10 mins):A coating for life 2LSU gets to the bottom of things -- in Antarctica 2Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2American Academy of Pediatric Dentistry Releases New Perinatal and Infant Oral Health Guidelines 48437 1American Academy of Pediatric Dentistry Releases New Perinatal and Infant Oral Health Guidelines 48437 2American Academy of Pediatric Dentistry Releases New Perinatal and Infant Oral Health Guidelines 48437 3American Academy of Pediatric Dentistry Releases New Perinatal and Infant Oral Health Guidelines 48437 4Summer Travel Destinations are Heavy on Fun and Sun 48434 1Summer Travel Destinations are Heavy on Fun and Sun 48434 2Summer Travel Destinations are Heavy on Fun and Sun 48434 3Access Pharmaceuticals Announces Granting of Two US Patents for MuGard 28TM 29 12562 1Access Pharmaceuticals Announces Granting of Two US Patents for MuGard 28TM 29 12562 2Access Pharmaceuticals Announces Granting of Two US Patents for MuGard 28TM 29 12562 3
...13, 2008, 1:00 p.m. ET) Research published in Natu...hibitors of a cell death pathway, termed necroptos...that can direct cells into necrosis. Induced by tr...f necrotic death can result in tissue damage contr...ings present a novel avenue for drug development. ...
...is available in Spanish . , This research work ...mperature change. Their main goal has been to dete...mperatures in Spain, explained to SINC the researc... University of Granada and main author, Matthias...m temperature series of every month since the end ...
...April 11, 2008) World War II-era physiologists hel..., research that helped pave the way for an Allied ...he University of South Florida College of Medicine...rical research for Monday, April 7, at the Experim...ation is entitled High altitude physiology researc...
Other Biology News:Stopping unwanted cell death: Implications for drug discovery 2Stopping unwanted cell death: Implications for drug discovery 3Scientists compiled 20th century temperature data in Spain as evidence of climatic change 2USF professor gives historical look at physiology and WWII air war 2USF professor gives historical look at physiology and WWII air war 3
Death Check II Assay System (TUNEL/Cell Viability) from Promega
Bovine Serum from Innovative Research
Mouse Anti-Mouse Qa.m8 Monoclonal Antibody, Unconjugated, Clone 5035-24.1 from CEDARLANE Laboratories Limited
...edium are recommended for protein expression from ...mbination has been selected based on rapid, vigoro...observed specifically with baculoviruses derived f...Ready-Plaque Sf9 Cells and BacVector Insect Cell M...
Biology Products: